P.O. Box 3660, Riyadh 11481, Mail Code 1515 (KAIMRC)
+966 (11) 429-4444
+966 (11) 429-4440

Publication

It was found that usual screening techniques in kidney transplants may not always be sufficient and more specific tests give better end results with fewer complications.

Name of Article:

Screening panel-reactive antibody negative, single-antigen positive: a case report

Author(s):

Jawdat D, Qurashi SA, Sayyari AA, Hajeer AH.

Journal:

Progress in Transplantation

Year of Publication:

2014

Publication Issue:

24(4)

Page Numbers:

341

Affiliation:

King Abdullah International Medical Research Center (KAIMRC), Riyadh, KSA; King Fahad National Guard Hospital

Shortlink:

bit.ly/1icmElD

Abstract:

Sensitized patients remain a challenge for successful transplant. Virtual crossmatch is used to determine the presence or absence of donor-specific antibodies. A 60-year-old woman with a negative screening for panel-reactive antibodies (PRA) received an A*11, A*68 type kidney with a negative anti-human globulin/complement-dependent cytotoxicity (AHG-CDC) crossmatch. Her transplant course was complicated by delayed graft function, and she required hemodialysis. On day 8 after receiving the transplant, she had a kidney biopsy that showed features of antibody-mediated rejection/severe acute tubular necrosis, which was treated by plasmapheresis for 5 sessions and intravenous immunoglobulin (2 g/kg). Her serum level of creatinine decreased from 6.7 to 3.6 mg/dL (600-320 mol/L). Panel-reactive antibody by Luminexx was repeated and again was negative. Single-antigen detection was tried next. Surprisingly, A*11:02 came up positive with a mean fluorescence intensity of 9500. High-resolution donor HLA type was A*68:01 and A*11:01. A*11:02 is not part of the screening Luminexx PRA whereas the 11:01 allele is. Serologically, HLA-A 11 has 2 defined splits, A11. 1 and A11. 2, which encode A*11:01 and A*11:02, respectively. In this case, the A*11:02 antibody does not seem to be responsible for the increasing creatinine level. However, if the donor had been A*11:02, a humeral rejection would have occurred and been missed by a virtual crossmatch. Thus virtual crossmatch may not work at all times. Screening for PRA by single antigens is suggested even in PRA-negative cases, if only virtual crossmatch is to be used.